Abbott Immunology

Abbott Immunology
Share
biotech/pharma

Abbott Immunology

 •  September 16, 2015

TORONTO, Sept. 16 2015 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it received Health Canada's approval of the TECNIS® Symfony Extended Range of Vision intraocular lens (IOL) for the treatment of people with cataracts who may also have a diminished ability to focus on near objects (presbyopia). It is the first and only extended range of ...

Abbott Immunology

 •  September 10, 2015

- Achieves top industry scores in all three categories of economic, environmental and social performance, and more than doubles the overall average industry score
- Abbott is only U.S.-based company among 24 global industry leaders
- Recognized for sustainability leadership on DJSI for 11 consecutive years
ABBOTT PARK, Ill., Sept. 10, 2015 ...

Abbott Immunology

 •  September 2, 2015

ABBOTT PARK, Ill., Sept. 2, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Abbott acquired the equity of Tendyne that it did not already own for $225 million upfront ...

Abbott Immunology

 •  September 1, 2015

- First Absorb™ Trial in Japan Meets Primary Endpoint
- Absorb is Designed to Leave Nothing Behind, Thus Allowing Restoration of the Vessel More Naturally Over Time, which Cannot Be Achieved with a Permanent Drug Eluting Stent (DES)
- More Than 100,000 People Worldwide with Coronary Artery Disease (CAD) Have Been Treated with Absorb1
LONDON, ...

Abbott Immunology

 •  July 30, 2015

- Acquisition of Tendyne Holdings, Inc. to Expand Abbott's Mitral Valve Therapies
- In Separate Transaction, Abbott Has Provided Capital and Secured an Option to Purchase Cephea Valve Technologies
ABBOTT PARK, Ill., July 30, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has entered into an agreement to purchase Tendyne Holdings, ...

Abbott Immunology

 •  July 22, 2015

- SECOND-QUARTER ADJUSTED AND GAAP EPS FROM CONTINUING OPERATIONS OF $0.52, ABOVE PREVIOUS GUIDANCE RANGE
- SECOND-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH
- ADVANCES SEVERAL NEW TECHNOLOGIES IN ITS MEDICAL DEVICES AND DIAGNOSTICS BUSINESSES
ABBOTT PARK, Ill., July 22, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results ...

Abbott Immunology

 •  July 1, 2015

ABBOTT PARK, Ill., July 1, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2015 financial results on Wednesday, July 22, 2015, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's ...

Abbott Immunology

 •  June 16, 2015

ABBOTT PARK, Ill., June 16, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) today confirmed its continued support for Mylan N.V's growth strategy by stating its intent to vote its 14.5 percent stake in Mylan in favor of Mylan's proposed acquisition of Perrigo."We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its ...

Abbott Immunology

 •  June 12, 2015

ABBOTT PARK, Ill., June 12, 2015 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 24 cents per share.This marks the 366th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2015, to shareholders of record at the close of business on July 15 ...

Abbott Immunology

 •  May 19, 2015

- More Than 100,000 People with Coronary Artery Disease Have Been Treated with Absorb
- Abbott on Track to Submit for Regulatory Approvals of Absorb in the U.S., Japan and China
PARIS, May 19, 2015 /PRNewswire/ -- Abbott announced today that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1™, which ...